Arrowhead Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) saw unusually large options trading on Monday. Stock traders bought 7,512 put options on the company. This is an increase of approximately 1,016% compared to the average volume of 673 put options.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock traded up $0.98 during trading hours on Monday, hitting $12.22. The company had a trading volume of 967,535 shares, compared to its average volume of 1,431,109. The firm has a 50-day moving average of $15.25 and a 200 day moving average of $18.59. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The firm has a market cap of $1.68 billion, a PE ratio of -2.36 and a beta of 0.99. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, sell-side analysts expect that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ARWR. Royal Bank of Canada reissued an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Chardan Capital reissued a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Finally, B. Riley reiterated a “buy” rating and set a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $41.44.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 51,425 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the transaction, the chief executive officer now directly owns 4,062,377 shares of the company’s stock, valued at approximately $61,220,021.39. This represents a 1.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 276,839 shares of company stock valued at $4,054,176 over the last 90 days. 4.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 0.9% during the third quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock worth $57,426,000 after purchasing an additional 26,171 shares during the period. World Investment Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 3.8% during the 3rd quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock worth $371,000 after acquiring an additional 700 shares during the period. Franklin Resources Inc. raised its holdings in Arrowhead Pharmaceuticals by 9.4% in the 3rd quarter. Franklin Resources Inc. now owns 19,251 shares of the biotechnology company’s stock valued at $373,000 after acquiring an additional 1,658 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Arrowhead Pharmaceuticals by 6.3% during the 4th quarter. Nordea Investment Management AB now owns 132,188 shares of the biotechnology company’s stock valued at $2,463,000 after acquiring an additional 7,776 shares during the period. Finally, First Citizens Bank & Trust Co. acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $205,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.